Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...

About 18.2% of those 81 or older, 13.1% of those 66–70, and 6.3% of those 71–80 years old have it. Individuals with a familial history of eczema, asthma, or hay fever have a heightened likelihood of ...

Jefferies raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $13 from $8 and keeps a Buy rating on the shares ahead of ...

The rising prevalence of allergic diseases such as food allergies, allergic rhinitis, asthma, and atopic dermatitis is a ...

The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune ...

TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to ...

The novel oral first-in-class anti-inflammatory agent has demonstrated robust efficacy and high safety margins in preclinical studies, and is the first drug candidate to advance to clinical trials ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...

13, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of artificial intelligence (AI)-based solutions for skin is excited to announce the publication of a case study ...